Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a versatile member of the ligandactivated nuclear hormone receptor superfamily of transcription factors, with expression in several different cell lines, especially in the digestive system. After being activated by its ligand, PPARγ can suppress the growth of oral, esophageal, gastric, colorectal, liver, biliary, and pancreatic tumor cells, suggesting that PPARγ ligand is a potential anticancer agent in PPARγ-expressing tumors. This review highlights key advances in understanding the effects of PPARγ ligands in the treatment of tumors in the digestive system.
Keywords: Antitumor, chemoprevention, digestive system, peroxisome proliferator-activated receptor γ, thiazolidinediones (TZDs), tumor cells.
Current Stem Cell Research & Therapy
Title:PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Volume: 11 Issue: 3
Author(s): Linjing Shu, Renhuan Huang, Songtao Wu, Zhaozhao Chen, Ke Sun, Yan Jiang and Xiaoxiao Cai
Affiliation:
Keywords: Antitumor, chemoprevention, digestive system, peroxisome proliferator-activated receptor γ, thiazolidinediones (TZDs), tumor cells.
Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a versatile member of the ligandactivated nuclear hormone receptor superfamily of transcription factors, with expression in several different cell lines, especially in the digestive system. After being activated by its ligand, PPARγ can suppress the growth of oral, esophageal, gastric, colorectal, liver, biliary, and pancreatic tumor cells, suggesting that PPARγ ligand is a potential anticancer agent in PPARγ-expressing tumors. This review highlights key advances in understanding the effects of PPARγ ligands in the treatment of tumors in the digestive system.
Export Options
About this article
Cite this article as:
Shu Linjing, Huang Renhuan, Wu Songtao, Chen Zhaozhao, Sun Ke, Jiang Yan and Cai Xiaoxiao, PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System, Current Stem Cell Research & Therapy 2016; 11 (3) . https://dx.doi.org/10.2174/1574888X10666150630111618
DOI https://dx.doi.org/10.2174/1574888X10666150630111618 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Opportunities and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging
Current Pharmaceutical Design Expression Level and Hormonal Regulation of ABC Transporters in Breast Cancer
Current Cancer Therapy Reviews Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters
Current Drug Delivery Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Aberrant Expression of CXCR4 Significantly Contributes to Metastasis and Predicts Poor Clinical Outcome in Breast Cancer
Current Molecular Medicine Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Current Pharmaceutical Design Th1-mediated Pathology in Mouse Models of Human Disease is Ameliorated by Concurrent Th2 Responses to Parasite Antigens
Current Topics in Medicinal Chemistry Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry Pharmacology of Appetite Suppression: Implication for the Treatment of Obesity
Current Drug Targets Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design The Role of Biomarker Genes in the Diagnosis and Treatment of Nonsmall Cell Lung Cancer
Current Respiratory Medicine Reviews Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Evaluation of Anti-Tumor Potential of <i>Lactobacillus acidophilus</i> ATCC4356 Culture Supernatants in MCF-7 Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry